OPTUS Pharmaceutical Dividends and Buybacks
Dividend criteria checks 0/6
OPTUS Pharmaceutical does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.06%
Buyback Yield
| Total Shareholder Yield | -0.06% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) 30% Share Price Surge Not Quite Adding Up
Jan 08
OPTUS Pharmaceutical's (KOSDAQ:131030) Profits Appear To Have Quality Issues
Nov 26Benign Growth For OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030) Underpins Stock's 25% Plummet
Nov 14Investors Could Be Concerned With OPTUS Pharmaceutical's (KOSDAQ:131030) Returns On Capital
Nov 13Capital Allocation Trends At OPTUS Pharmaceutical (KOSDAQ:131030) Aren't Ideal
Aug 07There's Reason For Concern Over OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Massive 28% Price Jump
Jun 27There's No Escaping OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Muted Earnings Despite A 43% Share Price Rise
Mar 25OPTUS Pharmaceutical's (KOSDAQ:131030) Earnings Are Of Questionable Quality
Mar 13The Returns On Capital At DHP Korea (KOSDAQ:131030) Don't Inspire Confidence
Apr 05DHP Korea's (KOSDAQ:131030) Problems Go Beyond Weak Profit
Mar 09DHP Korea Co., Ltd.'s (KOSDAQ:131030) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 10
How Much Did DHP Korea's(KOSDAQ:131030) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 12Should We Be Excited About The Trends Of Returns At DHP Korea (KOSDAQ:131030)?
Dec 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if A131030's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A131030's dividend payments have been increasing.
Dividend Yield vs Market
| OPTUS Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (A131030) | n/a |
| Market Bottom 25% (KR) | 1.2% |
| Market Top 25% (KR) | 4.0% |
| Industry Average (Medical Equipment) | 1.3% |
| Analyst forecast (A131030) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate A131030's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A131030's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate A131030's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A131030 has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 15:59 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OPTUS Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hee Kwak | Cape Investment & Securities Co., Ltd. |
| Yang Ju Park | Daishin Securities Co. Ltd. |
| Dong Oh Lim | IBK Securities Co. Ltd. |